PT3148517T - Composições e métodos para promover a formação óssea - Google Patents

Composições e métodos para promover a formação óssea

Info

Publication number
PT3148517T
PT3148517T PT157995440T PT15799544T PT3148517T PT 3148517 T PT3148517 T PT 3148517T PT 157995440 T PT157995440 T PT 157995440T PT 15799544 T PT15799544 T PT 15799544T PT 3148517 T PT3148517 T PT 3148517T
Authority
PT
Portugal
Prior art keywords
compositions
methods
bone formation
promote bone
promote
Prior art date
Application number
PT157995440T
Other languages
English (en)
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of PT3148517T publication Critical patent/PT3148517T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
PT157995440T 2014-05-30 2015-05-28 Composições e métodos para promover a formação óssea PT3148517T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462005359P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
PT3148517T true PT3148517T (pt) 2021-07-23

Family

ID=54699759

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157995440T PT3148517T (pt) 2014-05-30 2015-05-28 Composições e métodos para promover a formação óssea

Country Status (12)

Country Link
US (2) US10208306B2 (pt)
EP (2) EP3903772A1 (pt)
JP (2) JP6920196B2 (pt)
CN (2) CN106535880A (pt)
AU (3) AU2015267006B2 (pt)
CA (1) CA2984889C (pt)
DK (1) DK3148517T3 (pt)
ES (1) ES2881626T3 (pt)
HU (1) HUE055062T2 (pt)
PL (1) PL3148517T3 (pt)
PT (1) PT3148517T (pt)
WO (1) WO2015184059A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3903772A1 (en) * 2014-05-30 2021-11-03 The Research Foundation for The State University of New York Compositions and methods to promote bone formation
CN109432504B (zh) * 2018-11-27 2021-11-16 中国人民解放军总医院第四医学中心 一种成骨基因干预功能材料及其制备方法
US20210030746A1 (en) * 2019-07-15 2021-02-04 Rovaxa Methods and compositions for treating cancer
AU2021309336A1 (en) * 2020-07-17 2023-02-16 Zetagen Therapeutics, Inc. Methods and compositions to graft bone using iron excipients
WO2023150305A1 (en) * 2022-02-04 2023-08-10 Kim Seong Jin Method of making bone and cartilage
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US6270979B1 (en) 1993-06-23 2001-08-07 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic treatments
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
JP2000509377A (ja) * 1996-04-19 2000-07-25 ザイモジェネティクス，インコーポレイティド 骨形成を誘発するための方法
ATE326222T1 (de) 2000-03-15 2006-06-15 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
GB2463474B (en) * 2008-09-11 2012-05-02 Agency Science Tech & Res Therapeutic bone growth and regeneration
US9511093B2 (en) * 2009-03-23 2016-12-06 The Texas A & M University System Compositions of mesenchymal stem cells to regenerate bone
US8529933B2 (en) * 2009-07-27 2013-09-10 Warsaw Orthopedic, Inc. Biphasic calcium phosphate cement for drug delivery
EP3903772A1 (en) * 2014-05-30 2021-11-03 The Research Foundation for The State University of New York Compositions and methods to promote bone formation

Also Published As

Publication number Publication date
AU2015267006B2 (en) 2020-04-09
JP2017518369A (ja) 2017-07-06
WO2015184059A1 (en) 2015-12-03
JP6916918B2 (ja) 2021-08-11
EP3148517A4 (en) 2017-05-17
HUE055062T2 (hu) 2021-10-28
DK3148517T3 (da) 2021-07-26
AU2015267006A1 (en) 2016-12-08
JP6920196B2 (ja) 2021-08-18
US20150344882A1 (en) 2015-12-03
EP3148517B1 (en) 2021-04-28
US20190093109A1 (en) 2019-03-28
EP3148517A1 (en) 2017-04-05
CA2984889C (en) 2024-01-02
PL3148517T3 (pl) 2021-11-29
CA2984889A1 (en) 2015-12-03
AU2020204496B2 (en) 2022-03-31
CN106535880A (zh) 2017-03-22
AU2022203758A1 (en) 2022-06-23
AU2020204496A1 (en) 2020-07-23
ES2881626T3 (es) 2021-11-30
AU2022203758B2 (en) 2024-02-15
EP3903772A1 (en) 2021-11-03
US10208306B2 (en) 2019-02-19
CN116059376A (zh) 2023-05-05
JP2020097619A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
IL287789A (en) Mogroside compounds, methods for their preparation, preparations including them and their uses
HRP20192145T1 (hr) Pripravci nosača-antitijela i metode pripreme i uporabe istih
GB2535253B (en) Compositions and methods
IL249011A0 (en) Methods and preparations related to exosomes
ZA201607540B (en) Compositions and methods to treating hemoglobinopathies
ZA201702794B (en) Cellulose-containing compositions and methods of making same
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
GB2541833B (en) Improvements to implant surfaces
GB201417828D0 (en) New methods and compositions
IL246879A0 (en) Preparations of Epilimod and methods of using them
PL3148517T3 (pl) Kompozycje i sposoby do promowania tworzenia kości
HK1231395A1 (zh) 生物活性血紅素過氧化物酶組合物和使用方法
HK1243404A1 (zh) 色酰胺組合物和使用方法
IL251238B (en) Mineral-based compounds and their uses
GB201402915D0 (en) Compositions and methods
GB201403212D0 (en) Compositions and methods
GB201419559D0 (en) Therapeutic compositions and methods
HK1198930A1 (en) Piceatannol-containing composition and method of producing piceatannol-containing composition
GB201415759D0 (en) Accelerator compositions and methods
GB201418410D0 (en) use of compositions of matter
GB201412359D0 (en) Composition of objects
GB201412089D0 (en) Composition of objects